IN-VIVO UPTAKE OF LIPOSOMAL BENZOPORPHYRIN DERIVATIVE AND PHOTOTHROMBOSIS IN EXPERIMENTAL CORNEAL NEOVASCULARIZATION
IN-VIVO UPTAKE OF LIPOSOMAL BENZOPORPHYRIN DERIVATIVE AND PHOTOTHROMBOSIS IN EXPERIMENTAL CORNEAL NEOVASCULARIZATION
复制标题
DOI：
10.1002/lsm.1900170207
复制
发表时间：
1995-01-01
影响因子：
2.4
通讯作者：
BIRNGRUBER, R
中科院分区：
文献类型：
--
作者：
SCHMIDTERFURTH, U;HASAN, T;BIRNGRUBER, R
背景与目的：光动力学疗法（PDT）在实验上已成功地应用于新生血管的阻断。我们评价了一种新的光敏剂苯并卟啉衍生物（BPD）的血管闭塞潜力，目前在临床试验中。由于脂质体配制的BPD强烈结合到内源性低密度脂蛋白（LDL）静脉注射后，LDL作为载体提供BPD优先60增殖endothelial cells.Study Design/Materials and Methods：角膜neovascularizations in rabbits被用作模型。通过监测激光诱导荧光（LIF）来测量脂质体BPD在体内的时间依赖性摄取和保留。光血栓形成诱导使用染料激光发射在692 nm.Results：最大BPD浓度测定在60-90分钟postinjection确定治疗的最佳时间间隔。血管造影记录显示，低至10 J/cm（2）的暴露可实现完全且不可逆的新生血管闭塞。组织学检查显示选择性内皮损伤，邻近角膜基质或虹膜血管保持完整。使用BPD直接与LDL复合，表明使用LDL介导的pathway.Conclusion：我们建议BPD-PDT用于新生血管性疾病的选择性治疗。(C)1995 Wiley-Liss，Inc.
Background and Objective: Photodynamic therapy (PDT) has been used successfully to occlude neovascularizations experimentally. We evaluated the vasoocclusive potential of benzoporphyrin derivative (BPD), a new photosensitizer currently in clinical trials. Since liposomally formulated BPD strongly binds to endogenous low density lipoproteins (LDL) after i.v. injection, LDL act as carrier to deliver BPD preferentially 60 proliferating endothelial cells.Study Design/Materials and Methods: Corneal neovascularizations in rabbits were used as model. Time-dependent uptake and retention of liposomal BPD were measured in vivo by monitoring the laser-induced fluorescence (LIF). Photothrombosis was induced using a dye laser emitting at 692 nm.Results: A maximal BPD concentration was measured at 60-90 minutes postinjection determining the optimal time interval for treatment. Exposures as low as 10 J/cm(2) allowed complete and irreversible neovascular occlusion as documented angiographically. Histology revealed selective endothelial damage, adjacent corneal stroma, or iris vessels, remained intact. Identical results were obtained using BPD directly complexed with LDL suggesting use of a LDL-mediated pathway.Conclusion: We suggest BPD-PDT for a selective treatment of neovascular diseases. (C) 1995 Wiley-Liss, Inc.